Pediatric Intracranial Ependymoma - Recommendations for
First-Line Treatment from the German HIT-MED study group

J 2023

Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group

OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER et. al.

Basic information

Original name

Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group

Authors

Edition

Klinische Pädiatrie, Stuttgart, Georg Thieme Verlag, 2023, 0300-8630

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

SIOP

Impact factor

Impact factor: 1.000 in 2022

RIV identification code

RIV/00216224:90249/23:00132052

DOI

http://dx.doi.org/10.1055/a-2070-7572

UT WoS

001058665800004

Keywords (in Czech)

ependymoma; guideline; radiotherapy; chemotherapy; children

Keywords in English

ependymoma; guideline; radiotherapy; chemotherapy; children

Abstract

V originále

Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged > 1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.

Links

90249, large research infrastructures

Name: CZECRIN IV

Citovat

OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER, Kristian PAJTLER, Christian HAGEL, Ulrich-Wilhelm THOMALE, Gudrun FLEISCHHACK, Beate TIMMERMANN and Stefan RUTKOWSKI. Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group. Klinische Pädiatrie. Stuttgart: Georg Thieme Verlag, 2023, vol. 235, No 3, p. 167-177. ISSN 0300-8630. Available from: https://dx.doi.org/10.1055/a-2070-7572.

@article{2330760,
   author = {Obrecht, Denise and Mynarek, Martin and StickanandVerfuerth, Martina and Bison, Brigitte and Schueller, Ulrich and Pajtler, Kristian and Hagel, Christian and Thomale, UlrichandWilhelm and Fleischhack, Gudrun and Timmermann, Beate and Rutkowski, Stefan},
   article_location = {Stuttgart},
   article_number = {3},
   doi = {http://dx.doi.org/10.1055/a-2070-7572},
   keywords = {ependymoma; guideline; radiotherapy; chemotherapy; children},
   language = {eng},
   issn = {0300-8630},
   journal = {Klinische Pädiatrie},
   title = {Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group},
   url = {https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2070-7572},
   volume = {235},
   year = {2023}
}

TY  - JOUR
ID  - 2330760
AU  - Obrecht, Denise - Mynarek, Martin - Stickan-Verfuerth, Martina - Bison, Brigitte - Schueller, Ulrich - Pajtler, Kristian - Hagel, Christian - Thomale, Ulrich-Wilhelm - Fleischhack, Gudrun - Timmermann, Beate - Rutkowski, Stefan
PY  - 2023
TI  - Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group
JF  - Klinische Pädiatrie
VL  - 235
IS  - 3
SP  - 167-177
EP  - 167-177
PB  - Georg Thieme Verlag
SN  - 03008630
KW  - ependymoma
KW  - guideline
KW  - radiotherapy
KW  - chemotherapy
KW  - children
UR  - https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2070-7572
N2  - Biological subtypes of ependymoma (EPN) have been introduced by the recent WHO classification and appear to have great impact on the clinical course, but have not yet found their way into clinical risk stratification. Further, the overall unfavorable prognosis underlines the fact that current therapeutic strategies need further evaluation for improvement. To date, there is no international consensus regarding first-line treatment for children with intracranial EPN. Extent of resection is known to be the most important clinical risk factor, leading to the consensus that consequent evaluation for re-surgery of postoperative residual tumor needs to have highest priority. Furthermore, efficacy of local irradiation is unquestioned and recommended for patients aged > 1 year. In contrast, efficacy of chemotherapy is still under discussion. The European trial SIOP Ependymoma II aims at evaluating efficacy of different chemotherapy elements, leading to the recommendation to include German patients. The BIOMECA study, as biological accompanying study, aims at identifying new prognostic parameters. These results might help to develop targeted therapies for unfavorable biological subtypes. For patient who are not qualified for inclusion into the interventional strata, the HIT-MED Guidance 5.2 provides specific recommendations. This article is meant as an overview of national guidelines regarding diagnostics and treatment as well as of treatment according to the SIOP Ependymoma II trial protocol.
ER  -

OBRECHT, Denise, Martin MYNAREK, Martina STICKAN-VERFUERTH, Brigitte BISON, Ulrich SCHUELLER, Kristian PAJTLER, Christian HAGEL, Ulrich-Wilhelm THOMALE, Gudrun FLEISCHHACK, Beate TIMMERMANN and Stefan RUTKOWSKI. Pediatric Intracranial Ependymoma - Recommendations for First-Line Treatment from the German HIT-MED study group. \textit{Klinische Pädiatrie}. Stuttgart: Georg Thieme Verlag, 2023, vol.~235, No~3, p.~167-177. ISSN~0300-8630. Available from: https://dx.doi.org/10.1055/a-2070-7572.

Detailed Information on Publication Record